Results indicated that 73.7% (115/156) of CRC tumors had decreased average CpG methylation over the CEACAM5 promoter compared with the adjacent normal part, and 26.3% (41/156) of cases belonged to the increased CEACAM5 methylation group (Table 2). This evidence concerns the gene CEACAM5 and colorectal carcinoma.